Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 39Unknown 6Terminated 6Active not recruiting 3Withdrawn 2Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Prostatic Neoplasms 26Lymphoma, Large B-Cell, Diffuse 17Burkitt Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, T-Cell, Peripheral 8Lymphoma, Follicular 8Lymphoma, B-Cell 7Lymphoma 6Neoplasms 5Lymphoma, Non-Hodgkin 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Leukemia, Biphenotypic, Acute 3Recurrence 2Prostatic Neoplasms, Castration-Resistant 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Ovarian Neoplasms 2Myasthenia Gravis 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Diseases 1

Interventions

venetoclax 21Cyclophosphamide 14Cytarabine 12Azacitidine 8fludarabine 7Dexamethasone 5Daunorubicin 5ruxolitinib 4revumenib 4Trimethoprim, Sulfamethoxazole Drug Combination 4quizartinib 3pirtobrutinib 3gamma-Globulins 3fludarabine phosphate 3blinatumomab 3Tacrolimus 3Rituximab 3Palliative Care 3Inotuzumab Ozogamicin 3Granulocyte Colony-Stimulating Factor 3Decitabine 3Ciprofloxacin 3Blood Specimen Collection 3zanubrutinib 2ponatinib 2pembrolizumab 2ibrutinib 2aldesleukin 2acalabrutinib 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia × Prednisone × Clear all
NCT04747912 2026-06-05

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

University of Chicago

Phase 2 Recruiting
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05645718 2026-05-19

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
27 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡